Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Prostate-specific membrane antigen radioligand therapy of prostate cancer
Mohsen Beheshti
*
, Alexander Heinzel
, Dirk von Mallek
, Christian Filss
,
Felix M. Mottaghy
*
Corresponding author for this work
Beeldvorming
GROW - Innovative Cancer Diagnostics & Therapy
NUTRIM - Metabolic Health
Research output
:
Contribution to journal
›
(Systematic) Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Prostate-specific membrane antigen radioligand therapy of prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer
100%
Prostate-specific Antigen
100%
Radioligand Therapy
100%
Prostate Cancer Patients
25%
Therapeutic Approaches
25%
Clinical Performance
25%
Radiation Therapy
25%
Advanced Stage
25%
Routine Clinical Practice
25%
Clinical Toxicity
25%
Castration-resistant Prostate Cancer
25%
Academic Research
25%
Lutetium-177 (177Lu)
25%
Clinical Safety
25%
Beta Radiation
25%
Chal
25%
Alpha Radiation
25%
Targeted Radionuclide Therapy
25%
Actinium
25%
α-emitter
25%
Beta Emitters
25%
INIS
antigens
100%
cancer
100%
therapy
100%
prostate
100%
membranes
100%
radiotherapy
33%
patients
16%
safety
16%
reviews
16%
toxicity
16%
performance
16%
metastases
16%
castration
16%
lutetium 177
16%
actinium 225
16%
Medicine and Dentistry
Prostate Cancer
100%
Radioligand
100%
Prostate Specific Membrane Antigen
100%
Lutetium 177
25%
Targeted Radionuclide Therapy
25%
Actinium 225
25%
Radiation Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Radioligand
100%
Prostate Specific Membrane Antigen
100%
Radioisotope
25%
Lutetium 177
25%
Actinium 225
25%